A-337 (Klus Pharma)

N/A

Report date: 2024/11/15 10:00:01

Base Information

Drug NameA-337 (Klus Pharma)
Drug Alias NameA-337 (Klus Pharma)A337 (Klus Pharma)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants +[4] 
TargetsProgrammed death-ligand 1Cytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesKlus Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesKlus Pharma Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A